Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Sequencing recommendations for HER2-low metastatic breast cancer diverge according to hormone receptor status. Data indicates that patients with hormone receptor-positive disease benefit most from receiving T-DXD prior to a TROP-2 ADC, whereas patients with triple-negative tumors achieve superior outcomes by starting with a TROP-2 ADC before T-DXD.

Related Insights

HER2-directed TKIs (like zongertinib) and ADCs (trastuzumab-deruxtecan/TDXD) have different mechanisms, and clinical data shows they are effective when used sequentially. Zongertinib works post-TDXD, and vice-versa. However, there is no evidence to support using one HER2 TKI after another has failed.

After a triple-negative breast cancer patient progresses on a first-line TROP2 antibody-drug conjugate (ADC), experts advise against immediately sequencing another ADC. Due to suspected cross-resistance, the recommended strategy is to return to traditional chemotherapy agents like taxanes or carboplatin, which remain effective options, before considering another ADC in later lines.

Positive data from both DESTINY-Breast09 (TDXD-based) and PATINA (CDK4/6i maintenance) create a new dilemma. With similar PFS outcomes, the first-line choice for metastatic HER2+/HR+ patients now hinges on toxicity profiles and patient preference rather than a single efficacy winner.

The TROPION-PanTumor01 study showed that patients who progressed on the TROP2-ADC sacituzumab govitecan still achieved responses to a second TROP2-ADC, Dato-DXD. This suggests that targeting the same antigen with a different payload can overcome initial resistance, informing future treatment sequencing.

A significant clinical challenge is the sequencing of antibody-drug conjugates (ADCs). Retrospective data from large databases indicates that using a second TROP2-targeted ADC after a first one provides very limited efficacy, highlighting an urgent need for prospective trials to define optimal sequencing strategies and overcome resistance.

The DESTINY-Breast11 trial demonstrated superior pCR rates using neoadjuvant T-DXd followed by THP, but Dr. Nadine Tung cautions against treating all patients with maximally intensive therapy. Because two-thirds of ER-negative patients already achieve pCR with just four cycles of THP, universal escalation causes overtreatment. Instead, clinicians should reserve intensive antibody-drug conjugate regimens for patients with high tumor burden or unfavorable biology.

Trop-2 antibody-drug conjugates (ADCs) outperform chemotherapy in metastatic triple-negative breast cancer regardless of the patient's Trop-2 expression level. While higher expression correlates with better response, the ADCs are superior even in low-expressing tumors, making it an ineffective selection tool versus chemo.

Contrary to concerns about cross-resistance between HER2 antibody-drug conjugates (ADCs), retrospective data shows TDM-1 remains effective after progression on TDXD. This suggests the different cytotoxic payloads are key, allowing for effective sequencing and challenging the assumption that progression on one ADC class member precludes using another.

Clinicians should be cautious not to conflate the remarkable CNS activity of trastuzumab deruxtecan (T-DXd) in HER2-positive disease with that of other ADCs, like TROP2-ADCs, in HER2-low or negative settings. Data is emerging for TROP2-ADCs, but their CNS activity is expected to be much more modest.

Experts are more cautious about sequencing ADCs back-to-back in triple-negative breast cancer (TNBC) compared to less aggressive subtypes. A sobering 50% of TNBC patients do not receive treatment beyond the first line, making it critical to use the most effective therapy upfront rather than saving options for later.